Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The medical equipment maker is set to pay as much as $925m to buy its portfolio company that will enable Novo, Merck & Co and Samsung to exit.

UnitedHealth Group and Merck & Co are both in line for exits as Decipher Biosciences files for a $100m initial public offering.

Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.

Vera has picked up series C cash from investors including GV and Alexandria Venture Investments to help progress its Merck Group-licensed autoimmune disease drug candidate through clinical trials.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.

The KU Leuven spinout has completed another tranche of funding for its series B round featuring investments from the university.

Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.